Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PacOcdyingon Sep 29, 2018 7:57pm
111 Views
Post# 28715806

RE:Aeterna Zentaris Appoints Leslie Auld as CFO

RE:Aeterna Zentaris Appoints Leslie Auld as CFO

 

Short Positions for GEN
Symbol Report Date Volume Change Shares Issued % Float
T : GEN 2018-09-15 16,113 15,613 143,588,177 0.01
T : GEN 2018-08-31 500 -9,500 143,588,177 0.00
T : GEN 2018-08-15 10,000 0 143,288,177 0.01
T : GEN 2018-07-31 10,000 -26,000 143,288,177 0.01
T : GEN 2018-07-15 36,000 21,956 143,288,177 0.03
T : GEN 2018-06-30 14,044 -58,312 143,288,177 0.01
T : GEN 2018-06-15 72,356 62,056 143,288,177 0.05
T : GEN 2018-05-31 10,300 300 125,228,664 0.01
T : GEN 2018-05-15 10,000 8,400 125,228,664 0.01
T : GEN 2018-04-30 1,600 300 122,573,664 0.00
T : GEN 2018-04-15 1,300 -13,081 122,573,664 0.00
T : GEN 2018-03-31 14,381 -1,619 117,390,686 0.01
T : GEN 2018-03-15 16,000 -9,227 117,390,686 0.01
T : GEN 2018-02-28 25,227 24,427 117,390,686 0.02
T : GEN 2018-02-15 800 -79,200 114,670,686 0.00
T : GEN 2018-01-31 80,000 54,403 114,670,686 0.07
T : GEN 2018-01-15 25,597 19,597 103,286,294 0.02
T : GEN 2017-12-31 6,000 1,986 96,479,915 0.01
T : GEN 2017-12-15 4,014 4,014 96,479,915 0.00
T : GEN 2017-11-30 0 -1,500 96,479,915 0.00
T : GEN 2017-11-15 1,500 -2,618 96,479,915 0.00
T : GEN 2017-10-31 4,118 4,118 96,479,915 0.00
T : GEN 2017-10-15 0 -1,580 96,479,915 0.00
T : GEN 2017-09-30 1,580 -450 96,479,915 0.00
T : GEN 2017-09-15 2,030 1,811 96,479,915 0.00
T : GEN 2017-08-31 219 -346 96,479,915 0.00
T : GEN 2017-08-15 565 -1,935 96,479,915 0.00
T : GEN 2017-07-31 2,500 2,278 97,508,978 0.00
T : GEN 2017-07-15 222 -200 97,508,978 0.00
T : GEN 2017-06-30 422 122 91,920,300 0.00
T : GEN 2017-06-15 300 -3,725 87,929,627 0.00
T : GEN 2017-05-31 4,025 -3,975 87,929,627 0.00
T : GEN 2017-05-15 8,000 6,160 87,929,627 0.01
T : GEN 2017-04-30 1,840 -49,260 87,929,627 0.00
T : GEN 2017-04-15 51,100 50,135 81,655,229 0.06
T : GEN 2017-03-31 965 -9,035 81,655,229 0.00
T : GEN 2017-03-15 10,000 4,444 81,655,229 0.01
T : GEN 2017-02-28 5,556 -8,444 81,655,229 0.01
T : GEN 2017-02-15 14,000 13,397 81,655,229 0.02
T : GEN 2017-01-31 603 -212,943 81,655,229 0.00
T : GEN 2017-01-15 213,546 212,946 80,355,229 0.27
T : GEN 2016-12-31 600 117 80,355,229 0.00
T : GEN 2016-12-15 483 -1,270 79,408,944 0.00
T : GEN 2016-11-30 1,753 1,133 78,408,944 0.00
T : GEN 2016-11-15 620 120 76,761,267 0.00
T : GEN 2016-10-31 500 -6,031 76,761,267 0.00
T : GEN 2016-10-15 6,531 6,011 72,877,641 0.01
T : GEN 2016-09-30 520 -496 72,877,641 0.00
T : GEN 2016-09-15 1,016 416 72,538,939 0.00
T : GEN 2016-08-31 600 282 62,744,736 0.00
T : GEN 2016-08-15 318 18 62,744,736 0.00
T : GEN 2016-07-31 300 -1,601 62,744,736 0.00
T : GEN 2016-07-15 1,901 870 62,744,736 0.00
T : GEN 2016-06-30 1,031 931 62,744,736 0.00
T : GEN 2016-06-15 100 -500 62,744,736 0.00
T : GEN 2016-05-31 600 500 62,744,736 0.00
T : GEN 2016-05-15 100 -49,400 67,094,671 0.00
T : GEN 2016-04-30 49,500 49,100 62,744,736 0.08
T : GEN 2016-04-15 400 67 61,582,848 0.00
T : GEN 2016-03-31 333 333 55,965,694 0.00
T : GEN 2016-02-15 0 -143 55,965,694 0.00
T : GEN 2016-01-31 143 143 55,965,694 0.00
T : GEN 2015-12-31 0 -65,730 55,965,694 0.00
T : GEN 2015-12-15 65,730 9,130 55,965,694 0.12
T : GEN 2015-11-30 56,600 55,500 55,965,694 0.10
T : GEN 2015-11-15 1,100 1,100 55,965,694 0.00
T : GEN 2015-09-30 0 -3,500 55,965,694 0.00
T : GEN 2015-09-15 3,500 3,500 55,965,694 0.01
T : GEN 2015-06-30 0 -500 52,009,445 0.00
T : GEN 2015-06-15 500 -5,400 52,009,445 0.00
T : GEN 2015-05-31 5,900 5,900 52,009,445 0.01
T : GEN 2015-04-30 0 -200 51,991,945 0.00
T : GEN 2015-04-15 200 200 51,005,836 0.00
T : GEN 2014-12-31 0 -9,000 51,005,836 0.00
T : GEN 2014-12-15 9,000 4,900 51,005,836 0.02
T : GEN 2014-11-30 4,100 -21,700 51,005,836 0.01
T : GEN 2014-11-15 25,800 25,800 51,005,836 0.05
T : GEN 2014-10-15 0 -2,300 51,005,836 0.00
T : GEN 2014-09-30 2,300 500 51,005,836 0.00
T : GEN 2014-09-15 1,800 -200 51,005,836 0.00
T : GEN 2014-08-31 2,000 2,000 51,005,836 0.00
T : GEN 2014-08-15 0 -8,700 51,005,836 0.00
T : GEN 2014-07-31 8,700 5,500 51,005,836 0.02
T : GEN 2014-07-15 3,200 -4,700 51,005,836 0.01
T : GEN 2014-06-30 7,900 4,700 44,005,836 0.02
T : GEN 2014-06-15 3,200 -2,000 44,005,836 0.01
T : GEN 2014-05-31 5,200 2,400 44,005,836 0.01
T : GEN 2014-05-15 2,800 -1,000 44,005,836 0.01
T : GEN 2014-04-30 3,800 2,000 44,005,836 0.01
T : GEN 2014-04-15 1,800 -500 43,905,836 0.00
T : GEN 2014-03-31 2,300 500 43,905,836 0.01
T : GEN 2014-03-15 1,800 1,800 43,905,836 0.00
T : GEN 2014-02-15 0 -600 43,905,836 0.00
T : GEN 2014-01-31 600 -400 43,905,836 0.00
T : GEN 2014-01-15 1,000 1,000 43,905,836 0.00
T : GEN 2013-11-30 0 -6,100 33,744,883 0.00
T : GEN 2013-11-15 6,100 6,100 33,744,883 0.02
T : GEN 2013-10-15 0 -2,000 33,744,883 0.00
T : GEN 2013-09-30 2,000 2,000 33,744,883 0.01
T : GEN 2013-09-15 0 -400 33,744,883 0.00
T : GEN 2013-08-31 400 400 33,744,883 0.00
T : GEN 2013-08-15 0 -400 33,744,883 0.00
T : GEN 2013-07-31 400 400 33,744,883 0.00
T : GEN 2013-04-30 0 -143,000 33,744,883 0.00
T : GEN 2013-04-15 143,000 143,000 33,744,883 0.42
T : GEN 2012-11-30 0 -49,000 116,122,645 0.00

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities